The findings confirm that engagement data provides clinical signals that directly impact ROI.
Analysis further reveals specific measurement frequencies that drive clinical outcomes and bend the cost curve
new york, March 10, 2026 /PRNewswire/ — Dario Health Co., Ltd. (NASDAQ: DRIO) (the “Company”, “DarioHealth” or “Dario”), a global digital health leader, today announced the publication of new peer-reviewed research results in the United States. Frontiers of digital health Significant and sustained glycemic improvements were demonstrated among users of the Dario platform.
dario logo
An observational study titled ”Machine learning and engagement insights for personalized blood sugar management,” The research team analyzed real-world data from 22,414 adults with type 2 diabetes who had baseline blood sugar levels in the high-risk range. Researchers used advanced machine learning (“ML”) models and longitudinal mixed-effects analysis to identify distinct glycemic trajectories moderated by demographic, clinical, and engagement factors.
By applying a generalized linear mixed-effects tree model, the researchers uncovered key moderating factors that influence glycemic improvement. Importantly, the results suggest broadness across diverse user populations, as demonstrated by the lack of significant body mass index (“BMI”) differences between races. Higher levels of digital engagement, particularly frequent blood glucose monitoring and lifestyle activity tags, were associated with stronger and more sustained blood sugar improvements. Important and actionable insights identify 12 measurements per month as the threshold for blood sugar improvement.
“Our findings confirm that engagement is a clinical signal, not just a usage metric,” said Iffat Hershkovitz, Ph.D., vice president of clinical science at Dalio and senior author of the study. “We observed significant early reductions in blood sugar levels followed by sustained stabilization, especially among users who consistently monitored and utilized lifestyle tools. Machine learning allows us to translate these patterns into adaptive, data-driven strategies that optimize long-term diabetes management.”
“This study shows that digital health platforms can move beyond a one-size-fits-all approach,” said Dr. Omar Manejwala, Dalio’s chief medical officer. “By applying machine learning to real-world data at scale, we can identify which users respond best, when interventions are most effective, and how engagement behaviors impact outcomes. These insights allow us to dynamically personalize support and improve glycemic management in clinically meaningful ways.”
For employers, health plans and risk-taking organizations seeking scalable, evidence-based solutions, the results underscore Dalio’s ability to translate real-world data into measurable clinical impact for clients.
About DarioHealth Corp. (NASDAQ: DRIO)
DarioHealth Corp. (NASDAQ: DRIO) is a leading digital health company revolutionizing the way people with chronic conditions manage their health through a user-centric, multi-chronic disease digital treatment platform. Dario’s platform and suite of solutions deliver personalized, dynamic interventions for diabetes, hypertension, weight management, musculoskeletal pain, and behavioral health, driven by data analytics and one-on-one coaching.
Dario’s user-centric platform provides people with continuous, customized health care and disrupts traditional episodic approaches to healthcare. This approach enables people to holistically adapt their lifestyles towards sustainable behavior change, driving superior user satisfaction, retention and results, and making it easy to do the right thing.
Dario provides user-rated solutions to health plans and other payers, self-insured employers, healthcare providers, and consumers worldwide. For more information about Dario and its digital health solutions, please visit http://dariohealth.com.
This news release and related statements from DarioHealth Corp. representatives and partners contain or may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements that are not statements of historical fact may be considered forward-looking statements. For example, we use forward-looking statements in this press release to discuss the potential benefits of our platform, including how engagement data provides clinical signals that may impact ROI and improve long-term glycemic outcomes, and how machine learning analytics may enable more adaptive and personalized care strategies. Without limiting the generality of the foregoing, words such as “plan,” “project,” “potential,” “seek,” “may,” “will,” “expect,” “believe,” “anticipate,” “intend,” “could,” “estimate,” or “continue” are intended to identify forward-looking statements. Readers are cautioned that certain important factors may affect our actual results and could cause them to differ materially from the forward-looking statements made in this news release. Factors that may affect our results include, but are not limited to, regulatory approvals, product demand, market acceptance, competitive product and price effects, product development, commercialization or technical difficulties, negotiation and trade success, legal, social and economic risks, and risks related to the adequacy of existing cash resources. Other factors that may cause or contribute to differences between the Company’s actual results of operations and forward-looking statements include, without limitation, the risks discussed in the Company’s filings with the Securities and Exchange Commission. Readers are cautioned that actual results (including, without limitation, the timing and results of the Company’s Dario™ commercial and regulatory plans described herein) may differ materially from those described in the forward-looking statements. The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.
DarioHealth Corporate Contact
michael lipari Senior Vice President of Business Development irteam@dariohealth.com +1-201-785-6310
rob halpern Senior Vice President of Marketing irteam@dariohealth.com
Logo – https://mma.prnewswire.com/media/2866807/Dario_Logo.jpg
Sision
View original content: https://www.prnewswire.com/news-releases/dario-demonstrates-clinally-meaningful-blood-glucose-improvements-and-personalized-glycemic-trajectories-across-22-000-users-machine-learning-study-findings-published-in-frontiers-in-digital-health-302707687.html
